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Purpose: To describe a series of patients with Non-Hodgkin’s lymphoma (NHL) and 
concomitant eyelid carcinoma.
Methods: In this non-comparative interventional case series, we retrospectively 
reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
Results: The patients included one female and four male subjects. Systemic lymphoma 
had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma. 
The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two 
cases. The lymphoma was advanced (stage III or IV) in all patients. Four patients 
underwent surgical excision of the carcinoma and one patient was awaiting surgical 
treatment after completing systemic chemotherapy. Three subjects had high-grade 
carcinomas. Two patients had perineural invasion; one received adjuvant radiotherapy 
postoperatively but the other did not due to receiving systemic chemotherapy for 
recurrent NHL.
Conclusions: Systemic lymphoma may be associated with aggressive eyelid carcinomas.   
Perineural invasion is frequently encountered in this situation and should be treated 
with adjuvant radiation therapy to decrease the likelihood of local recurrence.
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INTRODuCTION
The incidence of non-Hodgkin’s lymphoma 
(NHL) is estimated to be rising 4% per year 
and to have doubled over the last two decades, 
especially in the industrialized world.1,2   
The literature suggests an increased risk of 
other malignancies in patients with NHL 
and chronic lymphocytic leukemia (CLL). 
Specifically, lung carcinoma, brain cancer, 
ocular melanoma, Hodgkin disease, and 
melanoma and non-melanoma skin cancers are 
over-represented among patients with NHL 
or CLL.3-6 In patients with NHL or CLL, skin 
cancer has not only an increased incidence 
but also a more aggressive behaviour.7 An 
increased propensity for and aggressive nature 
of skin cancers8 and more specifically eyelid 
cancers,9,10 has been reported in states of 
systemic immunosuppression, such as solid 
organ transplantation. A Medline search did 
not reveal any report of eyelid carcinoma 
in patients with systemic NHL. Herein, we 
report five patients with systemic NHL who 
developed eyelid skin carcinomas and present 
a brief review on this topic.Systemic Lymphoma and Eyelid Carcinoma; Shome et al
39 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2010; Vol. 5, No. 1
RESuLTS
The patients included four male and one female 
Caucasian subjects who had NHL and were 
treated between June 2001 and June 2007. They 
developed eyelid carcinoma from 1 to 72 months 
after a diagnosis of systemic lymphoma. Table 
1 summarizes patients’ data.
Patient 1
A 61-year-old man presented with a lesion 
involving the central left lower eyelid margin. 
He had been diagnosed with mantle cell 
lymphoma 6 years prior to this presentation. 
The patient was initially treated with rituximab 
and cyclophosphamide, doxorubicin, vincristine 
and prednisone (R-CHOP). However, upon 
recurrence, the patient received unrelated 
donor stem cell transplantation, 13 months 
prior to appearance of the eyelid mass. His 
post-transplant course had been complicated by 
recurrent viral infections, including influenza 
and cytomegalovirus (CMV) reactivation. He 
had developed basal cell carcinoma (BCC) in 
his forehead and chin three years ago and was 
treated with surgical excision. Pertinent physical 
findings consisted of a central area of ulceration, 
with telangiectasia and crusting in the left lower 
eyelid. The patient was neutropenic at diagnosis 
(white blood cell count=4000/fL). Incisional 
biopsy of the mass revealed a squamous cell 
carcinoma (SCC) in situ. The patient underwent 
wide local excision of the mass with frozen 
section control of the margins. The defect was 
repaired using a tarsoconjunctival flap (Hughes 
procedure) from the left upper eyelid with a full 
thickness skin graft harvested from the left upper 
eyelid. The patient did well postoperatively with 
no evidence of local or regional recurrence at 
last contact, 5 months after surgery.
Patient 2
A 61-year-old woman with a history of follicular 
NHL presented with a lesion in her left 
upper eyelid. Follicular lymphoma had been 
diagnosed three years ago and was being treated 
with chemotherapy (R-CHOP) at the time of 
presentation. She had a biopsy of the left upper 
eyelid lesion two years ago confirming BCC but 
the margins were not clear. When the patient 
presented to a Mohs surgeon, it was felt that 
the area of previous biopsy was undetectable 
and hence, further excision was deferred. The 
patient received no further intervention for this 
lesion and was under therapy for lymphoma 
in the interim. On examination, there was a 
well-circumscribed lesion at the upper eyelid 
margin. She was scheduled for surgical excision 
after completion of chemotherapy. The patient 
remains under close follow-up and there is only 
mild increase in the size of the lesion three 
months after initial presentation.
Table 1. Patients’ data
M,  Male;  F,  female;  R-CHOP,  Rituximab,  Cytoxan,  Hydroxydaunorubicin  (Adriamycin),  Oncovin  (Vincristine),  Prednisone/
Prednisolone; BMT, bone marrow transplantation; SCC, squamous cell carcinoma; BCC, basal cell carcinoma; RT, radiation therapy; 
DLBCL, diffuse large B-cell lymphoma
* This  patient  had  recurrence  of  lymphoma  at  the  same  time  as  recurrence  of  basal  cell  carcinoma  with  perineural  invasion. 
Postoperative adjuvant radiotherapy could not be carried out due to the need to start R-CHOP immediately and due to concerns for 
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1 61/M Mantle Cell, IV R-CHOP, BMT SCC 72 Surgery 5 Alive, well
2 61/F Follicular, III R-CHOP BCC 12 Observation 3 Alive, recurrence 
of lymphoma
3 65/M Follicular , IV R-CHOP BCC 1 Surgery, RT 
recommended*
5 Alive, recurrence 
of lymphoma
4 63/M Follicular, III A R-CHOP SCC 15 Surgery and  
post-op RT
6 Alive, well
5 76/M DLBCL, IV R-CHOP, RT 
(both orbits)
BCC 12 Surgery 36 Alive, wellSystemic Lymphoma and Eyelid Carcinoma; Shome et al
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Patient 3
A 65-year-old man with a history of transformed 
follicular NHL was noted to have a mass in his 
right lateral canthus. The patient had stage IV 
NHL with bone marrow involvement, initially 
diagnosed one year ago. He had been treated   
with 6 courses of R-CHOP chemotherapy and 
had a complete response. He had first noticed a 
lesion in the right lateral canthus, 11 months prior 
to presentation to our clinic. Tumor resection by 
Mohs surgery was performed and the histologic 
diagnosis confirmed a BCC. Over the past 4 to 
5 months, the patient has noted recurrence of 
the mass in the same area and the lesion had 
apparently almost doubled in size, in the month 
prior to presentation to our clinic. A recent biopsy 
showed BCC with a morpheaform (sclerosing) 
pattern and perineural invasion (Fig. 1).
On examination, there was an ulcerative 
mass in the right lateral canthus (Fig. 2A). This 
mass was removed in its entirety, with 4 mm 
free margins. The excision included 2/3 of 
the lower eyelid, 1/3 of the upper eyelid and 
much of the soft tissue in the lateral canthus 
down to the orbital rim. A tissue sampling 
from the inner side of the orbital rim was also 
performed. Margin clearance was confirmed on 
frozen section and complex repair of the defect 
in the right upper eyelid was performed using 
a tarsoconjunctival flap (Figures 2B and 2C). 
Adjuvant postoperative radiotherapy was 
recommended given the extensive perineural 
invasion seen on the surgical specimen but this 
could not be carried out because the patient 
was simultaneously found to have recurrence of 
systemic lymphoma and required treatment with 
R-CHOP; therefore excessive dermal toxicity 
was expected from radiation therapy combined 
with Adriamycin. The patient is currently 
under close observation for recurrence of the 
carcinoma and radiation will be performed 
after cessation of the chemotherapy regimen 
for systemic lymphoma.
Patient 4
A 63-year-old man with a history of stage 
Figure 2. A) Basal cell carcinoma of the right lower eyelid and lateral canthus. B) The surgical defect after resection of 
the mass with frozen section control of the margins. C) The defect was closed using a tarsoconjunctival flap and a full-
thickness skin graft. D) Final appearance after opening the flap and administration of postoperative adjuvant radiation 
therapy.
A B C D
Figure 1.  Histologic  section  of  a  basal  cell  carcinoma 
with perineural invasion (Hematoxylin and Eosin, 10×).Systemic Lymphoma and Eyelid Carcinoma; Shome et al
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III follicular NHL, presented with a poorly 
differentiated SCC of the left lower eyelid 
and cheek one year after a diagnosis of NHL. 
He had received R-CHOP for NHL, achieved 
complete remission and was still on maintenance 
Rituximab therapy when he developed the 
eyelid carcinoma. On examination, there was a 
lesion in the left lower eyelid and cheek in the 
distribution of the infraorbital nerve. A biopsy 
had revealed SCC with perineural invasion. The 
patient underwent surgical resection of this mass 
and infraorbital nerve dissection. He received 
postoperative adjuvant radiotherapy and has 
had no evidence of recurrence at last contact, 
6 months after completion of radiotherapy.
Patient 5
A 76-year-old man with a history of central 
nervous system lymphoma of large, diffuse, 
B-cell variety, and bilateral intraocular 
lymphoma, presented with a lesion in his 
lower eyelid and cheek that had been proven 
to be a BCC based on a recent biopsy. He 
had received systemic methotrexate and 
rituximab together with radiation therapy to 
both orbits, which had resulted in complete 
remission. On examination, there was an area 
of ulceration, with indurated margins, crusting 
and surrounding telangiectasia on the left lower 
eyelid, extending onto the cheek. Wide local 
excision of the lesion with frozen section control 
of the margins was performed. The patient has 
had no recurrence of eyelid carcinoma during 
3 years of follow-up.
DISCuSSION
We describe 5 patients with systemic lymphoma 
(mantle cell and follicular each in two, and 
diffuse large B-cell in one) who developed 
aggressive eyelid carcinoma (SCC in two 
and BCC in three patients). Lymphoma was 
advanced in all patients (stage III in two and 
stage IV in three). Three subjects had high-grade 
carcinomas and two had perineural invasion. 
Three cases had recurrent lesions after previous 
excision elsewhere. Eyelid cancers required 
complex reconstruction in four patients. 
In one patient (patient 4), a suprastructure 
maxillectomy with bone graft was needed in 
addition to eyelid reconstruction.
Otley7 analysed the highest-quality data 
examining the association between lymphoma 
and skin cancer, derived from population-
based studies in Denmark, Sweden and 
Switzerland.4,6,11-13 These studies and others 
show a significantly increased risk for both 
melanoma and non-melanoma skin cancer 
among patients with NHL/CLL. The association 
between skin cancer and NHL or CLL is present 
when analysis is performed both on populations 
of patients with NHL or CLL, and those with 
skin cancer. The consistency of this association 
suggests a strong link. In studies that analyze the 
incidence of skin cancer by sex, both men and 
women with NHL or CLL experience increased 
rates. The association becomes stronger as the 
population becomes older.7
Multiple pathogenic mechanisms have 
been postulated to explain the association 
between skin cancer and NHL. Some authors 
have proposed that the association represents 
a causal link among sunlight damage, skin 
cancer and NHL. The evidence regarding the 
association of NHL/CLL with exposure to 
ultraviolet (UV) radiation is contradictory; 
however, the link between UV radiation and 
skin cancer is well established.14-16
Multiple hypotheses center on disease-
related immunosuppression due to NHL as a 
cause of skin cancer, by which dysfunctional 
lymphocytes are unable to perform their usual 
immune surveillance and cytotoxic functions. 
This phenomenon most closely resembles 
immunosuppression related skin cancer in 
recipients of solid organ transplants.17 B cells 
have been shown to secrete immunosuppressive 
factors,18 and also to down-regulate CD40 
ligand (CD154) expression on activated T 
cells, resulting in impaired interaction between 
activated T-cell with normal B cells and other 
antigen-presenting cells.19 Another hypothesis 
is that patients with NHL have an inherent 
susceptibility to other cancers, including skin 
cancer, through a genetic abnormality, HLA-
associated variation, or environmental insults.20 
This hypothesis has not been systematically Systemic Lymphoma and Eyelid Carcinoma; Shome et al
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explored.
Finally, standard therapy for NHL includes 
administration of cytotoxic chemotherapy 
which could serve as a mutagenic stimulus 
for subsequent development of cancer. These 
agents are also profoundly immunosuppressive. 
Chlorambucil and cyclophosphamide, both 
alkylating agents, have been associated with an 
increased risk of acute myeloid leukemia, and 
there are multiple reports of newer nucleoside 
analogues, such as fludarabine, being associated 
with secondary malignancies, including skin 
cancer.20-22 A synergistic effect of alkylating 
agents and nucleoside analogues on second 
malignancies has been surmised.
Skin cancers behave more aggressively in 
patients with NHL, in that they are associated 
with higher rates of recurrence, metastasis and 
even death.23-25 Our experience in patients with 
multiple recurrent eyelid carcinomas described 
in this series corroborates with this observation. 
We recommend meticulous control of surgical 
margins on frozen section at the time of surgical 
excision of eyelid carcinoma and administration 
of postoperative adjuvant radiation therapy 
if perineural invasion is encountered. The 
administration of postoperative adjuvant 
radiation therapy is expected to decrease 
the likelihood of local recurrence for eyelid 
carcinomas that harbor microscopic perineural 
invasion.26
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